Usage and Dosage of Fosfomycin for NIH Category II Chronic Bacterial Prostatitis

Konstantinos Stamatiou, Gianpaolo Perletti, Vittorio Magri, Alberto Trinchieri

Abstract


Chronic bacterial prostatitis (CBP, NIH category II) is a difficult-
to-eradicate, recurring, chronic infection of the prostate,
often characterized by disabling symptoms, significantly reducing
the quality of life of patients. Fluoroquinolones have been
for many years first-line agents for treatment of this condition.
However, mounting pathogen resistance trends (especially in
Mediterranean countries like Greece and Italy) are progressively
restricting the usage of fluoroquinolones for treating many
Gram-positive or Gram-negative infections in the urological
field, and clinicians are increasingly treating bacterial prostatitis
by empirically administering agents which have not been
adequately tested in the frame of clinical trials.
In recent years, reports on the efficacy of the bactericidal antibiotic
fosfomycin on CBP have been published. Most articles
published so far are case reports, and only few case series or
cohort studies are available. The aim of this article is to review
the information published so far concerning the usage and dosage
of fosfomycin for treatment of chronic bacterial prostatitis.


Keywords


prostate;prostatitis;chronic bcaterial prostatitis;fosfomycin;Fluoroquinolones

Full Text:

PDF

References


Perletti G., Monti E., Magri V., Cai T., Cleves A., Trinchieri A., Montanari

E. The association between prostatitis and prostate cancer.

Systematic review and meta-analysis. Arch Ital Urol Androl. 2017

Dec 31;89(4):259-265

Jiang J., Li J., Yunxia Z., Zhu H., Liu J., Pumill C. The role of prostatitis

in prostate cancer: meta-analysis. PLoS One. 2013 Dec

;8(12):e85179

European associaiton of Urology Giodelines; available at: https://

uroweb.org/guideline/urological-infections/

Falagas M.E., Vouloumanou E.K., Samonis G., Vardakas K.Z. Fosfomycin.

Clin Microbiol Rev. 2016 Apr;29(2):321-47.

Cunha B.A., Gran A., Raza M. Persistent extended-spectrum β-

lactamase-positive Escherichia coli chronic prostatitis successfully

treated with a combination of fosfomycin and doxycycline. Int J

Antimicrob Agents. 2015 Apr;45(4):427-9.

Grayson M.L., Macesic N., Trevillyan J., Ellis A.G., Zeglinski P.T.,

Hewitt N.H., Gardiner B.J., Frauman A.G. Fosfomycin for Treatment

of Prostatitis: New Tricks for Old Dogs. Clin Infect Dis. 2015 Oct

;61(7):1141-3.

Gardiner B.J., Mahony A.A., Ellis A.G., Lawrentschuk N., Bolton

D.M., Zeglinski P.T., Frauman A.G., Grayson M.L. Is fosfomycin a

potential treatment alternative for multidrug-resistant gram-negative

prostatitis? Clin Infect Dis. 2014 Feb;58(4):e101-5.

Fan L., Shang X., Zhu J., Ma B., Zhang Q. Pharmacodynamic and

pharmacokinetic studies and prostatic tissue distribution of fosfomycin

tromethamine in bacterial prostatitis or normal rats.

Andrologia. 2018 Aug;50(6):e13021.

Zhanel G.G., Zhanel M.A., Karlowsky J.A. Oral Fosfomycin for the

Treatment of Acute and Chronic Bacterial Prostatitis Caused by

Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol.

Jan 30;2018:1404813.

Demonchy E., Courjon J., Ughetto E., Durand M., Risso K., Garraffo

R., Roger P.M. Cefoxitin-based antibiotic therapy for extended-

spectrum β-lactamase-producing Enterobacteriaceae

prostatitis: a prospective pilot study. Int J Antimicrob Agents. 2018

Jun;51(6):836-841.

Los-Arcos I., Pigrau C., Rodríguez-Pardo D., Fernández-Hidalgo

N., Andreu A., Larrosa N., Almirante B. Long-Term Fosfomycin-

Tromethamine Oral Therapy for Difficult-To-Treat Chronic

Bacterial Prostatitis. Antimicrob Agents Chemother. 2015 Dec

;60(3):1854-8.

Γ. Μακρής, Δ. Ζαβραδινός, Λ. Γεροπαπάς, Ρ. Αβακιάν, Κ. Σταματίου.

H φωσφομυκίνη και ο ρόλος της στη θεραπεία της ανθεκτικής και

πολυανθεκτικής χρόνιας βακτηριακής προστατίτιδας από gram-

αρνητικούς μικροοργανισμούς. 22ο Πανελλήνιο Ουρολογικό

Συνέδριο, At Ξενοδοχείο Creta Maris, Χερσόνησος Ηρακλείου,

Κρήτη, 2014. AA-145H.

Karaiskos I., Galani L., Sakka V., Gkoufa A., Sopilidis O., Chalikopoulos

D., Alivizatos G., Giamarellou E. Oral fosfomycin for the treatment

of chronic bacterial prostatitis. J Antimicrob Chemother. 2019

Feb 22. pii: dkz015. Doi: 10.1093/jac/dkz015 [Epub ahead of print]

PubMed PMID: 30796442.

Gian J., Cunha B.A. Raoultella planticola chronic bacterial prostatitis

with prostatic calcifications: successful treatment with prolonged

fosfomycin therapy. Int J Antimicrob Agents. 2016 May;47(5):414.

Guerin F., Henegar C., Spiridon G., Launay O., Salmon-Ceron D.,

Poyart C. Bacterial prostatitis due to Pseudomonas aeruginosa

harbouring the blaVIM-2 metallo-{beta}-lactamase gene from

Saudi Arabia. J Antimicrob Chemother. 2005 Sep;56(3):601-2.

Almeida F., Santos Silva A., Silva Pinto A., Sarmento A. Chronic

prostatitis caused by extended-spectrum β-lactamase-producing

Escherichia coli managed using oral fosfomycin - A case report.

IDCases. 2019 Jan 24;15:e00493.

Kumon H., Ono N., Iida M., Nickel J.C. Combination effect of fosfomycin

and ofloxacin against Pseudomonas aeruginosa growing in

a biofilm. Antimicrob Agents Chemother. 1995 May;39(5):1038-44.

Monden K., Ando E., Iida M., Kumon H. Role of fosfomycin in a

synergistic combination with ofloxacin against Pseudomonas

aeruginosa growing in a biofilm. J Infect Chemother. 2002

Sep;8(3):218-26.

Mikuniya T., Kato Y., Kariyama R., Monden K., Hikida M., Kumon

H. Synergistic effect of fosfomycin and fluoroquinolones against

Pseudomonas aeruginosa growing in a biofilm. Acta Med Okayama.

Oct;59(5):209-16.

https://pubchem.ncbi.nlm.nih.gov/compound/54331.




DOI: http://dx.doi.org/10.19264/hj.v31i2.268